Trevi Therapeutics annual shares outstanding
2018
2019
2020
2021
2022
2023
2024
2025
Trevi Therapeutics Shares Outstanding History (TRVI)
Trevi Therapeutics reported 128.3M shares outstanding at the end of fiscal 2025.
View full Trevi Therapeutics company overviewTrevi Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 128.3M | 34.7M | +37.08% |
| 2024 | 2024-12-31 | 93.6M | 25.3M | +37.08% |
| 2023 | 2023-12-31 | 68.3M | 8.3M | +13.91% |
| 2022 | 2022-12-31 | 59.9M | 31.4M | +110.29% |
| 2021 | 2021-12-31 | 28.5M | 10.0M | +53.70% |
| 2020 | 2020-12-31 | 18.5M | 712,216 | +3.99% |
| 2019 | 2019-12-31 | 17.8M | 17.4M | +3966.25% |
| 2018 | 2018-12-31 | 438,600 | — | — |
Trevi Therapeutics quarterly shares outstanding
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 142.4M | 20.6M | +16.95% |
| Q1 2026 | 2026-03-31 | 128.4M | 28.5M | +28.55% |
| Q4 2025 | 2025-12-31 | 128.3M | 34.7M | +37.08% |
| Q3 2025 | 2025-09-30 | 128.2M | 52.8M | +69.92% |
| Q2 2025 | 2025-06-30 | 121.8M | 49.2M | +67.75% |
| Q1 2025 | 2025-03-31 | 99.9M | 30.9M | +44.86% |
| Q4 2024 | 2024-12-31 | 93.6M | 25.3M | +37.08% |
| Q3 2024 | 2024-09-30 | 75.5M | 11.6M | +18.16% |
| Q2 2024 | 2024-06-30 | 72.6M | 9.5M | +15.05% |
| Q1 2024 | 2024-03-31 | 69.0M | 8.9M | +14.81% |
| Q4 2023 | 2023-12-31 | 68.3M | 8.3M | +13.91% |
| Q3 2023 | 2023-09-30 | 63.9M | 5.5M | +9.49% |
| Q2 2023 | 2023-06-30 | 63.1M | 23.4M | +58.86% |
| Q1 2023 | 2023-03-31 | 60.1M | 29.3M | +94.98% |
| Q4 2022 | 2022-12-31 | 59.9M | 31.4M | +110.29% |
| Q3 2022 | 2022-09-30 | 58.3M | 39.8M | +214.46% |
| Q2 2022 | 2022-06-30 | 39.7M | 18.3M | +85.09% |
| Q1 2022 | 2022-03-31 | 30.8M | 10.9M | +54.69% |
| Q4 2021 | 2021-12-31 | 28.5M | 10.0M | +53.70% |
| Q3 2021 | 2021-09-30 | 18.5M | 225,718 | +1.23% |
| Q2 2021 | 2021-06-30 | 21.5M | 3.6M | +20.21% |
| Q1 2021 | 2021-03-31 | 19.9M | 2.1M | +11.66% |
| Q4 2020 | 2020-12-31 | 18.5M | 712,216 | +3.99% |
| Q3 2020 | 2020-09-30 | 18.3M | 486,498 | +2.73% |
| Q2 2020 | 2020-06-30 | 17.9M | 16,582 | +0.09% |
| Q1 2020 | 2020-03-31 | 17.8M | 17.4M | +3966.25% |
| Q4 2019 | 2019-12-31 | 17.8M | 17.4M | +3966.25% |
| Q3 2019 | 2019-09-30 | 17.8M | — | — |
| Q2 2019 | 2019-06-30 | 17.8M | — | — |
| Q1 2019 | 2019-03-31 | 438,600 | — | — |
| Q4 2018 | 2018-12-31 | 438,600 | — | — |
Trevi Therapeutics shares outstanding trends
Over the last five reported fiscal years, Trevi Therapeutics's shares outstanding moved from 18.5M to 128.3M, a change of 109.8M. The latest reported quarter, Q2 2026, shows 142.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Trevi Therapeutics filings at SEC.gov ↗